Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q1 2022
Holdings as of Mar 31, 2022, filed May 16, 2022. Long positions only; changes compare share counts with Q4 2021.
- Positions
- 39
- −4 vs. Q4 2021
- Portfolio value
- $201.8M
- −$59.3M (−22.7%) vs. Q4 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 75,000 | $303.0K | 0.2% | −220,000−74.6% | Reduced | History |
| LRMRLarimar Therapeutics, Inc. | COM | 100,000 | $405.0K | 0.2% | −125,000−55.6% | Reduced | History |
| PRDSPardes Biosciences, Inc. | COM | 85,000 | $614.0K | 0.3% | +35,000+70.0% | Added | History |
| SYRESpyre Therapeutics, Inc. | COM | 686,599 | $1.58M | 0.8% | +686,599 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 1,315,154 | $1.63M | 0.8% | −684,846−34.2% | Reduced | History |
| MRTXMirati Therapeutics, Inc. | COM | 20,000 | $1.64M | 0.8% | −10,000−33.3% | Reduced | History |
| CYPHCypherpunk Technologies Inc. | COM | 993,714 | $1.74M | 0.9% | −356,286−26.4% | Reduced | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 473,562 | $1.80M | 0.9% | −430,663−47.6% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 85,000 | $1.87M | 0.9% | −33,344−28.2% | Reduced | History |
| NMTR9 Meters Biopharma, Inc. | COM | 3,250,000 | $1.95M | 1.0% | 00.0% | Unchanged | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 120,000 | $2.02M | 1.0% | −50,000−29.4% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 125,000 | $2.15M | 1.1% | −200,000−61.5% | Reduced | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 150,000 | $2.55M | 1.3% | −50,000−25.0% | Reduced | History |
| RLMDRelmada Therapeutics, Inc. | COM | 100,000 | $2.70M | 1.3% | −100,000−50.0% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 100,000 | $3.06M | 1.5% | 00.0% | Unchanged | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 200,000 | $3.17M | 1.6% | −225,000−52.9% | Reduced | History |
| DSGNDesign Therapeutics, Inc. | COM | 200,000 | $3.23M | 1.6% | +65,000+48.1% | Added | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 80,000 | $3.69M | 1.8% | 00.0% | Unchanged | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 750,000 | $3.74M | 1.9% | 00.0% | Unchanged | History |
| SRPTSarepta Therapeutics, Inc. | COM | 50,000 | $3.91M | 1.9% | −50,000−50.0% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 94,500 | $3.91M | 1.9% | +94,500 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 225,000 | $3.91M | 1.9% | −75,000−25.0% | Reduced | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 100,000 | $4.39M | 2.2% | +100,000 | New | History |
| RAPTRAPT Therapeutics, Inc. | COM | 250,000 | $5.50M | 2.7% | −100,000−28.6% | Reduced | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 350,000 | $5.69M | 2.8% | +350,000 | New | History |
| CTICCti Biopharma Corp | COM | 1,300,000 | $6.07M | 3.0% | +100,000+8.3% | Added | History |
| KZRKezar Life Sciences, Inc. | COM | 400,000 | $6.65M | 3.3% | +150,000+60.0% | Added | History |
| PCVXVaxcyte, Inc. | COM | 300,000 | $7.25M | 3.6% | +50,000+20.0% | Added | History |
| ARVNArvinas, Inc. | COM | 110,000 | $7.40M | 3.7% | 00.0% | Unchanged | History |
| ISEEIVERIC bio, Inc. | COM | 450,000 | $7.57M | 3.8% | −175,000−28.0% | Reduced | History |
| KRTXKaruna Therapeutics, Inc. | COM | 60,000 | $7.61M | 3.8% | +60,000 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 466,403 | $8.62M | 4.3% | −33,597−6.7% | Reduced | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 300,000 | $10.2M | 5.1% | −50,000−14.3% | Reduced | History |
| SRRASierra Oncology, Inc. | COM NEW | 325,000 | $10.4M | 5.2% | +75,000+30.0% | Added | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,100,000 | $10.4M | 5.2% | +600,000+120.0% | Added | History |
| MRUSMerus N.V. | COM | 400,000 | $10.6M | 5.2% | +50,000+14.3% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 250,000 | $12.7M | 6.3% | −75,000−23.1% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 1,700,000 | $12.7M | 6.3% | 00.0% | Unchanged | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 140,000 | $16.4M | 8.1% | −50,000−26.3% | Reduced | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q4 2021 (9)
Positions held at the end of Q4 2021 that are gone from this filing.
| Security | Class | Shares in Q4 2021 | Value in Q4 2021 | % of portfolio in Q4 2021 | History |
|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 30,000 | $5.09M | 1.9% | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 210,000 | $4.64M | 1.8% | History |
| Bellus Health Inc New07987C204 | COM NEW | 450,000 | $3.62M | 1.4% | – |
| KURAKura Oncology, Inc. | COM | 225,000 | $3.15M | 1.2% | History |
| GHRSGH Research PLC | ORDINARY SHARES | 100,000 | $2.33M | 0.9% | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 60,000 | $1.76M | 0.7% | History |
| IMUXImmunic, Inc. | COM | 165,000 | $1.58M | 0.6% | History |
| RETAReata Pharmaceuticals Inc | CL A | 55,000 | $1.45M | 0.6% | History |
| CABACabaletta Bio, Inc. | COM | 135,000 | $512.0K | 0.2% | History |